Dados do Trabalho
EXTRAPYRAMIDAL SYNDROME IN A NEWBORN EXPOSED TO QUETIAPINE IN UTERO
Apresentação do caso
The use of atypical antipsychotics is increasingly common, including in the population of childbearing age. In this study, the authors intend to report changes in the neurological examination of newborns exposed to quetiapine in utero
A full-term male patient presented with sensory decrease and hypotonia at birth, requiring neonatal resuscitation maneuvers. Mother had a complete prenatal care, negative STORCHZ serology and no reports of intercurrences during pregnancy, except for a depressive episode treated with quetiapine, 300mg/day, throughout pregnancy. The patient was born with an Apgar score of 1/3/6, cord blood gas analysis within the normal range. Shortly after birth, he evolved with the need for admission to the neonatal ICU and subsequent orotracheal intubation due to sensory decrease. He remained hemodynamically stable, without the need for vasoactive drugs. The neurological examination showed extrapyramidal signs, such as plastic hypertonia, cogwheel rigidity and trismus. Cerebrospinal fluid was collected and a tomography of the skull was performed, both normal. EEG presented with focal alterations in the right temporal region. He did not present seizures. The patient evolved with improvement of extrapyramidal symptoms from the fourth day of life, but these remained until the seventh day. Cranial magnetic resonance imaging showed no alterations. He was discharged from the hospital with 14 days of life, asymptomatic.
The use of atypical antipsychotics by pregnant women may increase the risk of respiratory dysfunction, extrapyramidal syndrome and withdrawal syndrome in the newborn.
Symptoms in the newborn may include agitation, eating disorder, hypertonia or hypotonia, respiratory distress, drowsiness, and tremor, and these effects may be self-limiting or require hospitalization.
Evidence regarding fetal risk is limited and, so far, it is not possible to state whether maternal use of antipsychotics increases the risk of fetal malformations.
There is no description of the duration of neurological symptoms secondary to the use of maternal quetiapine in newborns.
More studies are needed on the maternal use of atypical antipsychotics and it's effect in fetuses and newborns, since the available studies are still unable to define the safety of using these medications during pregnancy. Treatment and choice of medication should be individualized, weighing the maternal-fetal risk-benefit.
Referências (se houver)
Kulkarni J, Storch A, Baraniuk A, Gilbert H, Gavrilidis E, Worsley R. Antipsychotic use in pregnancy. Expert Opin Pharmacother. 2015 Jun;16(9):1335-45. doi: 10.1517/14656566.2015.1041501. PMID: 26001182
Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. doi:10.1111/acps.12479 [PubMed 26344706]
Liu X, Henriksen TB, Pedersen LH. Quetiapine treatment in the third trimester and neonatal morbidities. Am J Obstet Gynecol MFM. 2023 Mar 23;5(6):100942. doi: 10.1016/j.ajogmf.2023.100942. Epub ahead of print. PMID: 36965696.
Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214-1220. doi:10.1176/appi.ajp.2007.06111886 [PubMed 17671284]
extrapyramidal syndrome, neonatal, quetiapine, in utero
Fonte de Fomento (se houver)
Declaração de conflito de interesses de TODOS os autores
Os autores não apresentam conflitos de interesse
Hospital de Clínicas de Porto Alegre - Rio Grande do Sul - Brasil
Gabriel De Lellis Neto, Michele Michelin Becker, Andrea Lucia Corso, Aline da Costa Lourenço, Danielle Dutra Araújo, Hugo Leonardo Justo Horácio, Olivia Sorato Bezerra, Renata Yasmin Cardoso Sousa, Josemar Marchezan